Hair Loss on Zepbound (Tirzepatide): How Common Is It, How Bad Does It Get, and When Does It Stop?

At a glance

• Incidence (15 mg dose): 5.7% in SURMOUNT-1 vs. 1.0% placebo (Jastreboff et al., NEJM 2022)
• Typical onset: 2 to 4 months after significant weight loss begins
• Peak shedding window: Months 3 through 6
• Usual resolution: Self-limiting within 6 to 12 months once weight stabilizes
• First-line management: Ensure daily protein intake of 1.2 to 1.5 g/kg, check ferritin and zinc levels (Guo & Katta, Derm Pract Concept 2017)
• When to escalate: If shedding persists beyond 12 months or patchy bald spots appear, refer to dermatology to rule out other causes
• Discontinuation consideration: Hair loss alone rarely warrants stopping Zepbound; discuss risk-benefit with your prescriber

What the Trial Data Actually Show

The clearest numbers come from the SURMOUNT-1 trial, a 72-week, placebo-controlled study of 2,539 adults with obesity. Alopecia rates were dose-dependent: 3.2% at 5 mg, 4.6% at 10 mg, and 5.7% at 15 mg, versus 1.0% on placebo. That means the drug itself (or the weight loss it causes) adds roughly 4 to 5 extra cases per 100 patients at the top dose.

The SURMOUNT-2 trial in patients with type 2 diabetes and obesity reported similar signals, though the overall rates were slightly lower, likely because average weight loss was more modest in that population. The FDA prescribing label for Zepbound lists alopecia as an adverse reaction occurring in ≥1% of treated patients across all dose groups.

One critical detail: trials recorded "alopecia" as a single adverse-event category. They did not sub-classify by type (telogen effluvium vs. androgenetic vs. alopecia areata). The clinical consensus, based on the timing and pattern of shedding, is that virtually all of these cases represent telogen effluvium (TE), the diffuse shedding pattern linked to physiologic stress.

Why Rapid Weight Loss Causes Hair to Fall Out

Hair follicles cycle through three phases: anagen (growth, lasting 2 to 7 years), catagen (transition, about 2 weeks), and telogen (rest, roughly 3 months). At any given time, about 85% to 90% of scalp hairs are in anagen. TE occurs when a stressor pushes a disproportionate number of follicles from anagen into telogen simultaneously. After the standard 3-month telogen rest period, those hairs shed together, producing the alarming clumps patients notice in the shower or on their pillow.

Rapid caloric deficit is a well-established TE trigger (Malkud, Int J Trichology 2015). Zepbound can produce 15% to 22% total body weight loss over 72 weeks. That rate of loss creates metabolic signals, including shifts in insulin, leptin, and IGF-1, that the follicle interprets as systemic stress. The hair itself is not damaged. The follicle simply enters a premature rest phase.

Micronutrient depletion compounds the problem. Patients eating significantly fewer calories often fall short on protein, iron, zinc, and biotin, all of which are required for normal keratin synthesis. Iron deficiency in particular (ferritin <40 mcg/L) has a well-documented association with increased TE severity (Trost et al., JAAD 2006).

Who Is Most Likely to Experience It

Not everyone on Zepbound will shed hair. Several factors raise the probability:

Higher weight loss magnitude. Patients losing >15% of baseline weight are more likely to develop TE than those with more moderate loss. The dose-dependent alopecia rates in SURMOUNT-1 closely mirror the dose-dependent weight loss curves: more loss, more shedding.

Speed of loss. Losing weight quickly in the first 3 to 4 months carries more follicular risk than a slower, steadier trajectory. Patients who respond aggressively to the initial dose escalation may notice shedding earlier.

Pre-existing nutritional gaps. People entering treatment with low ferritin, low zinc, or inadequate protein intake have less metabolic buffer. A 2017 review of nutritional factors in hair loss found that correcting deficiencies before or during caloric restriction measurably reduced TE episodes.

Female sex. Women report TE more frequently than men across all causes, partly because longer anagen-phase hair makes shedding more visible and partly because of hormonal differences in follicle cycling (Malkud, 2015).

History of TE. If you have had stress-related shedding before (postpartum, after surgery, after a crash diet), you are statistically more susceptible to a repeat episode.

Severity: What "Hair Loss" Actually Looks Like

The word "alopecia" in a trial table can terrify patients. Context matters. The vast majority of TE on Zepbound is mild to moderate diffuse thinning, not bald patches.

Clinically, mild TE means you notice more hairs on your brush or in the drain. Moderate TE means a visible decrease in ponytail thickness or scalp show-through under bright light. Severe TE, where others notice the thinning unprompted, is uncommon. Trial adverse-event tables did not report severity grades for alopecia, but the FDA label did not flag any cases as serious adverse events, and no discontinuations were attributed solely to hair loss in the published SURMOUNT data.

A practical self-assessment: the "hair pull test." Grasp about 60 hairs between your thumb and forefinger near the scalp and tug gently. Extracting more than 6 hairs (10%) suggests active TE (McDonald et al., JAAD 2017). This is a rough screen, not a diagnosis, but it can help you decide whether to bring the concern to your clinician.

Timeline: When It Starts, Peaks, and Stops

The typical TE arc on Zepbound follows a predictable pattern:

Months 1 to 2: Weight loss accelerates during dose titration. Follicles begin shifting into telogen, but you will not notice anything yet because the telogen rest phase has not completed.

Months 3 to 4: Shedding becomes noticeable. This is when most patients first report increased hair fall. The lag matches the standard 3-month telogen duration.

Months 4 to 6: Peak shedding. This is often the most distressing window. Daily hair counts may double or triple baseline.

Months 6 to 9: As weight loss decelerates (most patients approach a plateau by this point), new anagen hairs begin replacing shed telogen hairs. Shedding volume decreases.

Months 9 to 12: Visible regrowth in most patients. Short "baby hairs" along the hairline and part line are a reliable sign of recovery.

This timeline aligns with TE resolution patterns described in the dermatology literature. If shedding continues beyond 12 months without any improvement, the diagnosis may not be TE, and a dermatology referral is warranted to evaluate for chronic telogen effluvium or concurrent androgenetic alopecia.

Reducing Severity While Staying on Treatment

Stopping Zepbound is rarely necessary for hair loss alone. The following strategies can reduce TE severity without interrupting therapy:

Protein intake. Aim for 1.2 to 1.5 g of protein per kg of body weight daily. On a reduced-calorie diet, this requires deliberate planning. Hair is almost entirely keratin, a protein, and inadequate amino acid supply directly limits follicle output.

Check and correct ferritin. Ask your prescriber to check serum ferritin. If it is below 40 mcg/L, iron supplementation (typically 65 mg elemental iron daily with vitamin C for absorption) can shorten TE duration (Trost et al., JAAD 2006). Do not supplement iron without lab confirmation, because excess iron carries its own risks.

Zinc. Serum zinc below 70 mcg/dL is associated with increased shedding. A daily supplement of 30 mg zinc gluconate is a reasonable empiric approach if levels are borderline or low (Guo & Katta, 2017).

Avoid additional follicular stress. Tight hairstyles, heat styling, and chemical treatments add mechanical and thermal stress to already-vulnerable follicles. Gentle handling during active shedding phases makes a measurable difference.

Dose adjustment conversations. If shedding is severe and distressing, discuss with your prescriber whether a temporary hold at a lower dose (slowing the rate of weight loss) might reduce the trigger intensity. This is a clinical judgment call that balances metabolic benefit against quality-of-life impact.

When to See a Dermatologist

Most TE from Zepbound does not need specialty evaluation. Seek a dermatology referral if:

• Shedding has not improved at all after 12 months of stable weight
• You notice distinct bald patches rather than diffuse thinning (this could indicate alopecia areata, a different condition)
• Scalp itching, scaling, or redness accompanies the hair loss
• You had significant hair thinning before starting Zepbound

A dermatologist can perform a scalp biopsy or trichoscopy to confirm the diagnosis and rule out overlapping conditions.

Frequently asked questions

›

›

›

›

›

›

›

›

›

›

References

• Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
• Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626. doi:10.1016/S0140-6736(23)01200-X
• FDA. Zepbound (tirzepatide) prescribing information. 2023. accessdata.fda.gov
• Malkud S. Telogen effluvium: a review. Int J Trichology. 2015;7(3):108-113. PMC4606321
• Guo EL, Katta R. Diet and hair loss: effects of nutrient deficiency and supplement use. Dermatol Pract Concept. 2017;7(1):1-10. PMC5315033
• Trost LB, Bergfeld WF, Calogeras E. The diagnosis and treatment of iron deficiency and its potential relationship to hair loss. J Am Acad Dermatol. 2006;54(5):824-844. doi:10.1016/j.jaad.2005.11.1104
• Patel DP, Swink SM, Castelo-Soccio L. A review of the use of biotin for hair loss. Skin Appendage Disord. 2017;3(3):166-169. PMC5582478
• Hughes EC, Saleh D. Telogen effluvium. In: StatPearls. StatPearls Publishing; 2024. NBK430848